Immucell Corporation was originally established in Maine in 1982 and reorganized in Delaware in 1987 with its initial public offering of common stock. Immucell's purpose is to create practical products that stand the test of science and will have a significant economic impact on the animal health, dairy and beef industries. Immucell is a publicly traded biotechnology company engaged in research and development, production and sales of products that improve animal health and increase dairy and beef production. The company's product focus includes the prevention, diagnosis and treatment of bovine diseases with important economic benefits. 

ImmuCell Corporation (ICCC) stock fell 8.8% despite reporting an 11.5% YoY increase in Q2 product sales to $7.19 million and a significant rise in earnings to 20 cents per share. Net income rose to $1.84 million from $502,000, but gross profit declined to $2.44 million from $2.82 million. Adjusted EBITDA increased to $2.69 million from $1.36 million. Domestic sales climbed 27.7% to $6.2 million in Q2, while international sales fell 38.9% to $1 million.

Immucell

ImmuCell Q2 Earnings & Sales Up, Shares Fall 8.8%

ImmuCell plans to expand its liquids production capacity by approximately $4.5 million, aiming for over three times its current capacity by the end of 2027. This move comes after the company made significant changes in 2025 to focus on the calf scours market, invest in leadership, sales force expansion, and manufacturing. The expansion is expected to enhance ImmuCell's ability to meet growing demand for its products.

ImmuCell plans $4.5M expansion to boost capacity by 3x by 2027

ImmuCell Corporation reported Q2 2026 net income of $1.8 million, up from the previous year, driven by a settlement payment from a former contract manufacturer. Revenue grew 11.5% to $7.2 million, with distributors' out-the-door volume growth accelerating to 28%. The company's Tri-Shield product remained its primary growth driver, while Dual-Force sales increased to distribution and Functional Feed gained traction. Gross margin was 34%, reflecting low manufacturing volumes and the absorption of expenses related to a discontinued development program.

ImmuCell Q2 Revenue Up 11.5% to $7.2mln, Net Income Hits $1.8mln

At 10:00 AM on July 29, 2026, the 15-minute chart for Immucell triggered a MACD Death Cross and a KDJ Death Cross. This indicates that the stock price has the potential to continue declining, as the momentum of the stock price has shifted towards the downside and may further decrease.At 10:00 AM on July 29, 2026, technical indicators on the 15-minute chart for Immucell (IMUX) showed a [MACD Death Cross and KDJ Death Cross][1]. These signals are commonly used by traders to assess momentum shifts in stock prices. A MACD Death Cross occurs when the MACD line crosses below the signal line, while a KDJ Death Cross happens when the K line crosses below the D line. Both events are often interpreted as bearish signals, suggesting that [downward momentum may be gaining strength][1].Analysts and traders monitoring these indicators may view the developments as a potential sign of continued price weakness in the near term. However, it is important to note that technical indicators should be used in conjunction with other forms of analysis and market context to make informed investment decisions. Investors are advised to consider broader market conditions, company fundamentals, and risk tolerance when evaluating their positions.

伊芙美尔医疗

Immunic

Immucell's 15-Min Chart Triggers MACD Death Cross, KDJ Death Cross

According to the 15-minute chart for Immucell, two significant technical indicators have been triggered: the MACD Death Cross and the KDJ Death Cross, both occurring on July 28, 2026 at 11:15. This indicates that the stock price has the potential to continue its downward trend, with the momentum of the stock price shifting towards the downside. Consequently, there is a possibility for further decreases in the stock price.On July 28, 2026 at 11:15, the 15-minute chart for Immucell (IMUX) showed the activation of two key technical indicators: the MACD Death Cross and the KDJ Death Cross. These signals are often interpreted as bearish, suggesting a potential continuation of the stock’s downward trend. The MACD Death Cross occurs when the MACD line crosses below the signal line, typically indicating <a href="https://example.com">weakening momentum and shift</a>[1]. Similarly, the KDJ Death Cross, which involves the stochastic oscillator’s K and D lines, <a href="https://example.com">reinforces further price declines</a>[2]. While these indicators do not guarantee future price movements, they are widely used by technical analysts to assess market direction and momentum. Investors are advised to consider these signals in conjunction with broader market conditions and fundamental analysis before making trading decisions. As with all technical indicators, confirmation from subsequent price action is recommended to validate the potential for a sustained downward trend.

ICCC News